ANI Pharmaceuticals Inc (ANIP) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

Total Assets Chart for ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc (ANIP) total assets for FY2025 were USD 1.4B, a 12.2% change from FY2024. ANI Pharmaceuticals Inc's total assets grew from USD 3.4M in 1998 to USD 1.4B in 2025 (41658.0% over 27 years). Total assets compound annual growth rate: 5-year CAGR of 25.6%, 10-year CAGR of 17.6%, 20-year CAGR of 28.5%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$1.66B
Implied Share Price
$72.32
Enterprise Value
$1.94B
Revenue (TTM)
$978.38M
EBITDA
$209.41M
Profit Margin
11.07%
Trailing P/E
15.65
Forward P/E
7.12
Price/Book (MRQ)
2.86
Price/Sales (TTM)
1.70
EV/EBITDA
7.94
EV/Revenue
1.99
Dividend Yield
—
Book Value
$27.87
Free Cash Flow (FY2025)
$150.90M
Free Cash Flow Yield
9.09%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.